Protalix BioTherapeutics (PLX) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.62 -5.76%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
More
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $10 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
